Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | MAPK10 | P53779 | 4/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.37 |
| ▸ | TERT | O14746 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24359770 | 0.83 | PDE10A (0.42) | NPC1MAPTRAB9ASMN1; SMN2LMNA | |
| SCHEMBL20320623 | 0.80 | KMT2A (0.53) | NPC1MAPTRAB9ASMN1; SMN2LMNA | |
| SCHEMBL21893501 | 0.80 | MAPK10 (0.46) | NPC1RAB9ASMN1; SMN2LMNATSHR | |
| SCHEMBL18136489 | 0.79 | SMN1; SMN2 (0.46) | NPC1MAPTRAB9ASMN1; SMN2LMNA | |
| SCHEMBL11075652 | 0.78 | PTGS2 (0.43) | NPC1MAPTRAB9ASMN1; SMN2LMNA | |
| SCHEMBL20320622 | 0.76 | BRAF (0.41) | MAPTRAB9AL3MBTL1MAPK10MAPK9 | |
| SCHEMBL1825048 | 0.75 | TDP1 (0.65) | NPC1MAPTRAB9ASMN1; SMN2LMNA | |
| SCHEMBL13936258 | 0.73 | MAPK10 (0.40) | NPC1MAPTRAB9ASMN1; SMN2LMNA | |
| SCHEMBL1823842 | 0.72 | LMNA (0.67) | MAPTLMNAL3MBTL1PDE4DTDP1 | |
| SCHEMBL1824527 | 0.72 | L3MBTL1 (0.53) | NPC1MAPTRAB9ALMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3564232-B1 | BMP-SIGNAL-INHIBITING COMPOUND | RIKEN (JP) | 2022-01-26 | — | — | EP | disclosed |
| US-10954216-B2 | BMP-signal-inhibiting compound | RIKEN (JP) | 2021-03-23 | — | — | US | disclosed |
| US-20190337926-A1 | BMP-SIGNAL-INHIBITING COMPOUND | RIKEN (JP) | 2019-11-07 | — | — | US | disclosed |
| EP-3564232-A1 | BMP-SIGNAL-INHIBITING COMPOUND | Riken (JP) | 2019-11-06 | — | — | EP | disclosed |
| US-20150232429-A1 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE | 2015-08-20 | — | — | US | disclosed |
| US-9018205-B2 | Substituted pyrimidinyl-amines as protein kinase inhibitors | THE SCRIPPS RESEARCH INSTITUTE (US) | 2015-04-28 | — | — | US | disclosed |
| EP-2200436-B1 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS | SCRIPPS RESEARCH INST (US) | 2015-01-21 | — | — | EP | disclosed |
| US-8530480-B2 | Substituted pyrimidinyl-amines as protein kinase inhibitors | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-09-10 | — | — | US | disclosed |
| US-20130231336-A1 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-09-05 | — | — | US | disclosed |
| US-20100298312-A1 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2010-11-25 | — | — | US | disclosed |
| EP-2200436-A1 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS | The Scripps Research Institute (US) | 2010-06-30 | — | — | EP | disclosed |
| WO-2009032861-A1 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2009-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10954216-B2 | BMP-signal-inhibiting compound | BMP1, BMP2, BMP4 | NPC1 2815/4885MAPT 4782/4885RAB9A 1809/4885 |
| US-20190337926-A1 | BMP-SIGNAL-INHIBITING COMPOUND | BMP1, BMP2, BMPR2 | NPC1 2975/4885MAPT 4243/4885RAB9A 1632/4885 |
| US-20130231336-A1 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS | MAP3K20, MAP3K5, MAP3K7 | NPC1 2489/4885MAPT 1055/4885RAB9A 2773/4885 |
| US-20100298312-A1 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS | MAP3K20, MAP3K5, MAP3K7 | NPC1 2489/4885MAPT 1055/4885RAB9A 2773/4885 |
| US-20150232429-A1 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS | MAP3K20, MAP3K5, MAP3K7 | NPC1 2489/4885MAPT 1055/4885RAB9A 2773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.